|
Olympus reviewed the following literature titled "comparison of double-layer large-diameter and conventional small-diameter plastic stents for preoperative biliary drainage in resectable distal malignant biliary obstruction." literature summary: the use of a plastic stent (ps) in resectable patients with distal malignant biliary obstruction (dmbo) is uncommon due to the high failure rate of this method.This study evaluated the efficacy and safety of a double-layer, large-diameter ps as a bridge to surgery compared with a conventional ps.This was a single-center retrospective cohort study.In total, 129 consecutive patients with dmbo underwent pancreaticoduodenectomy between january 2011 and march 2018.Fifty-five patients who preoperatively underwent plastic biliary drainage were enrolled.The patients were divided into two groups based on stent diameter: a large-diameter plastic stent (lps) group and a small-diameter plastic stent (sps) group.The primary endpoint was the stent patency period, and the secondary endpoint was the medical cost.Thirty-six patients received spss; 19 patients received lpss.The patency rate until surgery was significantly higher in the lps group than in the sps group (89.5% vs.41.7%, p = 0.0006).Multivariate analysis revealed that lps use was significantly associated with sufficient stent patency.The total cost of lps use was significantly lower than that of sps use.Lpss had longer patency and reduced medical costs than spss.Lpss may be suitable for patients with dmbo who are scheduled to undergo surgery.Materials and methods the lps group received a 10-fr dls (double-layer stent, olympus medical systems, tokyo, japan).Stent placement complications and stent dysfunction.Regarding the complications related to stent placement, four patients experienced mild pancreatitis: 3 patients (8%) received an sps, and one patient received an lps (9%).However, according to the japanese guidelines for the management of acute pancreatitis, no severe ercp-related pancreatitis developed.Stent dysfunction before surgery occurred in a total of 23 patients.The patency rate of the lps group was significantly higher than that of the sps group (89.5% vs.41.7%, p =0.0006).The median number of stent dysfunction events was 0 in the lps group and 1 in the sps group, for a significantly lower rate in the lps group than in the sps group (p=0.0034).The kaplan¿meier curve also showed that stent patency was significantly longer in the lps group than in the sps group.Specifically, the 41-day stent patency rate (as stated, 41 days was the median interval time to surgery at our institution) was higher in the lps group than in the sps group (89% vs.46%, p =0.0034) (fig.2).The cause of stent dysfunction in the lps group included migration of the stent (one patient) and occlusion of the stent with jaundice (one patient); the case with migration involved impaction at the cystic duct.Type of events/number of patients event 1: serious adverse events postoperative complication, present - 7 patients all infection complications - 5 patients.Surgical site infection - 2 patients.Cholangitis - 1 patient.Pancreatic fistula - 3 patients.Delayed gastric emptying - 2 patients.Stent placement complications.Pancreatitis (1 patient).Event 2: malfunction with serious adverse events.Stent migration with impaction at the stent duct (1 patient).Stent occlusion with jaundice (1 patient).
|
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Since the subject device was not returned to olympus for evaluation, the reported issue was not confirmed.Based on the results of the investigation, it is believed that the reported event was not caused by a defect with the olympus device.However, the root cause could not be identified.This supplemental report includes additional information received from the author.B5 updated accordingly.Also, a correction has been made to e1 from the initial medwatch.Olympus will continue to monitor field performance for this device.
|